home / stock / annx / annx news

ANNX News and Press, Annexon Inc. From 01/12/26

Stock Information
Company Name: Annexon Inc.
Stock Symbol: ANNX
Market: NASDAQ
Website: annexonbio.com
Menu
ANNX ANNX Quote ANNX Short ANNX News ANNX Articles ANNX Message Board
Get ANNX Alerts

News, Short Squeeze, Breakout and More Instantly...
ANNX - Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for  Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half...
ANNX - Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advanc...

ANNX - Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Lov...

ANNX - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announc...
ANNX - Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

2025-11-20 17:23:49 ET The last time I spoke about Annexon Inc. ( ANNX ) it was with respect to a Seeking Alpha article entitled " Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck ". With respect to this article, I went over the company's lea...

ANNX - Annexon stock rises after director purchases shares

2025-11-20 12:02:19 ET More on Annexon Biosciences Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating ...

ANNX - Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announc...
ANNX - Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announc...

ANNX - Annexon launches $75M public offering of common stock

2025-11-12 16:22:05 ET More on Annexon Biosciences Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating ...

ANNX - Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced a...
Previous 10 Next 10